Dear Reader: Innovations across the entire package - Pharma ...
Dear Reader: Innovations across the entire package - Pharma ...
Dear Reader: Innovations across the entire package - Pharma ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Excipients & Actives for <strong>Pharma</strong><br />
No. 26, 2011<br />
Solutions without argon<br />
Solutions with argon<br />
100<br />
100<br />
80<br />
Kollidon 30 LP<br />
80<br />
Ascorbic acid content [%]<br />
60<br />
40<br />
PVP<br />
PVP peroxide enriched<br />
Ascorbic acid<br />
60<br />
40<br />
20<br />
20<br />
0<br />
0 20 40 60 80 100<br />
0<br />
0 20 40 60 80 100<br />
Day<br />
Day<br />
FIGURE 1<br />
Stability of ascorbic acid in different povidone solutions incubated at 25°C /60% r.h.<br />
Hydrocortisone [%]<br />
100<br />
98<br />
96<br />
94<br />
Solutions without argon<br />
Conclusion<br />
• Using Kollidon ® 30 LP in <strong>the</strong> formulation of<br />
actives highly sensitive to oxidation can significantly<br />
improve drug stability.<br />
• A correlation was found between <strong>the</strong> peroxide<br />
content and <strong>the</strong> stability of <strong>the</strong> model actives.<br />
• Fur<strong>the</strong>r investigations to underline <strong>the</strong> effectiveness<br />
of Kollidon 30 LP in a dry state will<br />
be reported soon.<br />
92<br />
Kollidon 30 LP<br />
PVP<br />
PVP peroxide enriched<br />
90<br />
0 20 40 60 80 100<br />
Day<br />
FIGURE 2<br />
Stability of hydrocortisone in different povidone solutions incubated at 25°C /60% r.h.<br />
Page 12
Change language